FDA's Graham To Present Overview At COX-2 Advisory Committee Meeting
This article was originally published in The Pink Sheet Daily
Executive Summary
Office of Drug Safety Director for Science & Medicine David Graham is scheduled to present an "epidemiological overview" on Feb. 16, day one of the three-day meeting. Senate Finance Committee Chairman Charles Grassley is concerned that FDA has forbidden Graham from discussing certain data.